BioCryst Pharma (BCRX) Misses Q3 EPS by 3c
Get Alerts BCRX Hot Sheet
Price: $5.08 -1.36%
EPS Growth %: +25.0%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
FSI, RELV, NEOM, More
EPS Growth %: +25.0%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
FSI, RELV, NEOM, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $3.77 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- P3 Health Partners Inc. (PIII) Misses Q4 EPS by 14c, reaffirms guidance
- Dolphin Entertainment, Inc. (DLPN) Misses Q4 EPS by 33c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!